De novo nonalcoholic fatty liver disease after liver transplantation

Suk Seo, Kalyani Maganti, Manjit Khehra, Rajendra Ramsamooj, Alexander Tsodikov, Christopher Bowlus, John McVicar, Mark A Zern, Natalia J Torok

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Hepatic steatosis is a recognized problem in patients after orthotopic liver transplant (OLT). However, de novo development of nonalcoholic fatty liver disease (NAFLD) has not been well described. The aim of this study was to determine the prevalence and predictors of de novo NAFLD after OLT. A retrospective analysis was performed on 68 OLT patients with donor liver biopsies and posttransplantation liver biopsies. Individual medical charts were reviewed for demographics, indication for OLT, serial histology reports, genotypes for hepatitis C, comorbid conditions, and medications. Liver biopsies were reviewed blindly and graded according to the Brunt Scoring System. Multivariate logistic regression analysis was used to study the risk factors for developing NAFLD. The interval time from OLT to subsequent follow-up liver biopsy was 28 ± 18 months. A total of 12 patients (18%) developed de novo NAFLD, and 6 (9%) developed de novo NASH. The regression model indicated that the use of angiotensin-converting enzyme inhibitors (ACE-I) was associated with a reduced risk of developing NAFLD after OLT (odds ratio, 0.09; 95% confidence interval, 0.010-0.92; P = 0.042). Increase in body mass index (BMI) of greater than 10% after OLT was associated with a higher risk of developing NAFLD (odds ratio, 19.38; 95% confidence interval, 3.50-107.40; P = 0.001). In conclusion, de novo NAFLD is common in the post-OLT setting, with a significant association with weight gain after transplant. The use of an ACE-I may reduce the risk of developing post-OLT NAFLD.

Original languageEnglish (US)
Pages (from-to)844-847
Number of pages4
JournalLiver Transplantation
Volume13
Issue number6
DOIs
StatePublished - Jun 2007

Fingerprint

Liver Transplantation
Liver
Transplants
Biopsy
Non-alcoholic Fatty Liver Disease
Angiotensin-Converting Enzyme Inhibitors
Odds Ratio
Confidence Intervals
Hepatitis C
Weight Gain
Histology
Body Mass Index
Logistic Models
Genotype
Regression Analysis
Demography
Tissue Donors

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

De novo nonalcoholic fatty liver disease after liver transplantation. / Seo, Suk; Maganti, Kalyani; Khehra, Manjit; Ramsamooj, Rajendra; Tsodikov, Alexander; Bowlus, Christopher; McVicar, John; Zern, Mark A; Torok, Natalia J.

In: Liver Transplantation, Vol. 13, No. 6, 06.2007, p. 844-847.

Research output: Contribution to journalArticle

Seo, S, Maganti, K, Khehra, M, Ramsamooj, R, Tsodikov, A, Bowlus, C, McVicar, J, Zern, MA & Torok, NJ 2007, 'De novo nonalcoholic fatty liver disease after liver transplantation', Liver Transplantation, vol. 13, no. 6, pp. 844-847. https://doi.org/10.1002/lt.20932
Seo, Suk ; Maganti, Kalyani ; Khehra, Manjit ; Ramsamooj, Rajendra ; Tsodikov, Alexander ; Bowlus, Christopher ; McVicar, John ; Zern, Mark A ; Torok, Natalia J. / De novo nonalcoholic fatty liver disease after liver transplantation. In: Liver Transplantation. 2007 ; Vol. 13, No. 6. pp. 844-847.
@article{58d7d78d2264443fa1feda88d8e909de,
title = "De novo nonalcoholic fatty liver disease after liver transplantation",
abstract = "Hepatic steatosis is a recognized problem in patients after orthotopic liver transplant (OLT). However, de novo development of nonalcoholic fatty liver disease (NAFLD) has not been well described. The aim of this study was to determine the prevalence and predictors of de novo NAFLD after OLT. A retrospective analysis was performed on 68 OLT patients with donor liver biopsies and posttransplantation liver biopsies. Individual medical charts were reviewed for demographics, indication for OLT, serial histology reports, genotypes for hepatitis C, comorbid conditions, and medications. Liver biopsies were reviewed blindly and graded according to the Brunt Scoring System. Multivariate logistic regression analysis was used to study the risk factors for developing NAFLD. The interval time from OLT to subsequent follow-up liver biopsy was 28 ± 18 months. A total of 12 patients (18{\%}) developed de novo NAFLD, and 6 (9{\%}) developed de novo NASH. The regression model indicated that the use of angiotensin-converting enzyme inhibitors (ACE-I) was associated with a reduced risk of developing NAFLD after OLT (odds ratio, 0.09; 95{\%} confidence interval, 0.010-0.92; P = 0.042). Increase in body mass index (BMI) of greater than 10{\%} after OLT was associated with a higher risk of developing NAFLD (odds ratio, 19.38; 95{\%} confidence interval, 3.50-107.40; P = 0.001). In conclusion, de novo NAFLD is common in the post-OLT setting, with a significant association with weight gain after transplant. The use of an ACE-I may reduce the risk of developing post-OLT NAFLD.",
author = "Suk Seo and Kalyani Maganti and Manjit Khehra and Rajendra Ramsamooj and Alexander Tsodikov and Christopher Bowlus and John McVicar and Zern, {Mark A} and Torok, {Natalia J}",
year = "2007",
month = "6",
doi = "10.1002/lt.20932",
language = "English (US)",
volume = "13",
pages = "844--847",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - De novo nonalcoholic fatty liver disease after liver transplantation

AU - Seo, Suk

AU - Maganti, Kalyani

AU - Khehra, Manjit

AU - Ramsamooj, Rajendra

AU - Tsodikov, Alexander

AU - Bowlus, Christopher

AU - McVicar, John

AU - Zern, Mark A

AU - Torok, Natalia J

PY - 2007/6

Y1 - 2007/6

N2 - Hepatic steatosis is a recognized problem in patients after orthotopic liver transplant (OLT). However, de novo development of nonalcoholic fatty liver disease (NAFLD) has not been well described. The aim of this study was to determine the prevalence and predictors of de novo NAFLD after OLT. A retrospective analysis was performed on 68 OLT patients with donor liver biopsies and posttransplantation liver biopsies. Individual medical charts were reviewed for demographics, indication for OLT, serial histology reports, genotypes for hepatitis C, comorbid conditions, and medications. Liver biopsies were reviewed blindly and graded according to the Brunt Scoring System. Multivariate logistic regression analysis was used to study the risk factors for developing NAFLD. The interval time from OLT to subsequent follow-up liver biopsy was 28 ± 18 months. A total of 12 patients (18%) developed de novo NAFLD, and 6 (9%) developed de novo NASH. The regression model indicated that the use of angiotensin-converting enzyme inhibitors (ACE-I) was associated with a reduced risk of developing NAFLD after OLT (odds ratio, 0.09; 95% confidence interval, 0.010-0.92; P = 0.042). Increase in body mass index (BMI) of greater than 10% after OLT was associated with a higher risk of developing NAFLD (odds ratio, 19.38; 95% confidence interval, 3.50-107.40; P = 0.001). In conclusion, de novo NAFLD is common in the post-OLT setting, with a significant association with weight gain after transplant. The use of an ACE-I may reduce the risk of developing post-OLT NAFLD.

AB - Hepatic steatosis is a recognized problem in patients after orthotopic liver transplant (OLT). However, de novo development of nonalcoholic fatty liver disease (NAFLD) has not been well described. The aim of this study was to determine the prevalence and predictors of de novo NAFLD after OLT. A retrospective analysis was performed on 68 OLT patients with donor liver biopsies and posttransplantation liver biopsies. Individual medical charts were reviewed for demographics, indication for OLT, serial histology reports, genotypes for hepatitis C, comorbid conditions, and medications. Liver biopsies were reviewed blindly and graded according to the Brunt Scoring System. Multivariate logistic regression analysis was used to study the risk factors for developing NAFLD. The interval time from OLT to subsequent follow-up liver biopsy was 28 ± 18 months. A total of 12 patients (18%) developed de novo NAFLD, and 6 (9%) developed de novo NASH. The regression model indicated that the use of angiotensin-converting enzyme inhibitors (ACE-I) was associated with a reduced risk of developing NAFLD after OLT (odds ratio, 0.09; 95% confidence interval, 0.010-0.92; P = 0.042). Increase in body mass index (BMI) of greater than 10% after OLT was associated with a higher risk of developing NAFLD (odds ratio, 19.38; 95% confidence interval, 3.50-107.40; P = 0.001). In conclusion, de novo NAFLD is common in the post-OLT setting, with a significant association with weight gain after transplant. The use of an ACE-I may reduce the risk of developing post-OLT NAFLD.

UR - http://www.scopus.com/inward/record.url?scp=34250688169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250688169&partnerID=8YFLogxK

U2 - 10.1002/lt.20932

DO - 10.1002/lt.20932

M3 - Article

C2 - 17029282

AN - SCOPUS:34250688169

VL - 13

SP - 844

EP - 847

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 6

ER -